RISS 검색 - 국내학술지논문

무료
기관 내 무료
유료

내보내기
내책장담기
한글로보기

정확도순

내림차순

내림차순

10개씩 출력

1
Auditory P300 after Taking Hypnotic Zolpidem

KyoungUk Lee,E Jin Park,ChinYang Kang,SangIck Han,KweonHaeng Lee,YangWhan Jeon 대한신경정신의학회 2007 PSYCHIATRY INVESTIGATION Vol.4 No.1
- 원문보기 2
  ScienceON
  
  스콜라
Objective-Although the hypnotic, zolpidem, is known to be free of any detrimental residual effects, its residual effects on cognitive function after its elimination half-life have not been sufficiently investigated. This study was designed to examine the residual effects of zolpidem on cognitive function using event-related potentials (ERPs). Methods-Twelve healthy right-handed men participated in this study. ERP recordings were conducted at baseline and 5 hours after taking 10 mg of zolpidem. The auditory oddball task included the presentation of a series of standard (1,000 Hz, 75 dB, 80%) and target tones (2,000 Hz, 75 dB, 20%) in a predetermined quasi-random order. The data were analyzed using analysis of variance (ANOVA). Results-On the behavioral task, the reaction time was significantly delayed in the post-drug condition compared to the baseline. The P300 amplitude was significantly decreased in the post-drug condition compared to the baseline. However, the P300 latency showed no difference between the pre- and post-drug conditions. Conclusions-The residual effects of zolpidem on cognitive function may persist after its elimination half-life. Further large placebo-controlled trials are needed to confirm the findings of this study.
2
The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder

YoungHoon Ko,KyoungSae Na,ChulEung Kim,SeungHyun Kim,YangWhan Jeon,JungSeo,MoonSoo Lee,ShinGyeom Kim,HyunGhang Jeong,HanYong Jung 대한신경정신의학회 2014 PSYCHIATRY INVESTIGATION Vol.11 No.4
- 원문보기 2
  KCI
  
  스콜라
Objective-Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics. Methods-A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile–including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels–were measured at each follow-up visit. Results-The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles. Conclusion-Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period.
3
Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics

JungSun Lee,Seockhoon Chung,JoonNoh Lee,JunSoo Kwon,DoHoon Kim,ChulEung Kim,KangSeob Oh,YangWhan Jeon,MinSoo Lee,MyungHo Lim,HyeRyein Chang,ChangYoon Kim 대한신경정신의학회 2010 PSYCHIATRY INVESTIGATION Vol.7 No.3
- 원문보기 3
  ScienceON
  
  KCI
  
  스콜라
Objective-To determine if the maintenance effectiveness and tolerability of aripiprazole demonstrated in a 12-week study were maintained in an extension phase (up to 26 weeks). Methods-This study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically stable patients with schizophrenia or schizoaffective disorder. All the patients were randomly assigned to the aripiprazole group or the non-aripiprazole group. The effectiveness analysis consisted of the comparison of the upper bound of the 95% confidence interval (CI) of the mean Clinical Global Impression-Improvement (CGI-I) score to 4 (no change) at the end of the study. Results-At the baseline, the aripiprazole group (n=135) and the non-aripiprazole group (n=31) were comparable with respect to their mean ages, gender distribution, baseline Positive and Negative Syndrome Scale scores, and Clinical Global Impression-Severity (CGI-S) scores. The study showed that the mean CGI-I score was 2.92 (95% CI: 2.72-3.12) in the aripiprazole group and 2.81 (95% CI: 2.35-3.26) in the non-aripiprazole group at 26 weeks. In the aripiprazole group, the remission rates at 12 and 26 weeks were 74.8% and 72.6%, respectively, and 80.2% of the patients with remission at 12 weeks maintained their remission state until the end of the study. About one-fourth of the patients in the aripiprazole group reported one or more spontaneous treatment-emergent adverse events, such as insomnia, headache, and nausea. Conclusion-This study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks.